Expertise in
13
conditions

Hansjurgen T. Agostini

Freiburg, BW, DE 
Expertise in
13
conditions
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Hansjurgen Agostini practices in Freiburg, Germany. Agostini is highly rated in 13 conditions, according to our data. Their top areas of expertise are Hemangioblastoma, Age-Related Macular Degeneration (ARMD), Von Hippel-Lindau (VHL) Syndrome, Late-Onset Retinal Degeneration, and Vitrectomy.

Their clinical research consists of co-authoring 154 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Freiburg, BW, Germany
Other Locations
Salem, BW, Germany
Tuebingen, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)
Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Other
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Drugs: 5-Fluorouracil, Low molecular weight heparin
Study Phase: Phase 3
View 1 Less Clinical Trial

154 Total Publications

A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration.
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration.
Journal: Expert opinion on biological therapy
Published: June 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Agostini's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile